Arca
Skip to content

Hypersensitivity

Drug research and approvals for hypersensitivity: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 1,212 studies of hypersensitivity are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, FDA has 3 approved and 0 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 1,212
  • Trials authorized in Canada: 0
  • FDA orphan approvals: 3
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 1,212 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

51 approved, 15 in phase 3, 32 in phase 2, 11 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Desloratadine, Cetirizine, Levocetirizine, Chlorpheniramine, Pseudoephedrine, Promethazine, Fexofenadine, Brompheniramine, Loratadine, Clemastine, Rupatadine, Glycerin, Astemizole, Terfenadine, Methapyrilene, Carbinoxamine, Thenalidine, Phenol, Methylpromazine, Epinastine, Cyclizine, Cyproheptadine, Azatadine, Dexbrompheniramine, Azelastine, Pyrilamine, Methdilazine, Bromodiphenhydramine, Meclizine, Acrivastine, Triprolidine, Tripelennamine, Diphenhydramine, Pheniramine, Diphenylpyraline, Ketotifen, Buclizine, Dimenhydrinate, Thiethylperazine, Dextromethorphan and 11 more

Dexamethasone
Phase 3 Glucocorticoid receptor agonist
Butenafine
Phase 3 Squalene monooxygenase inhibitor
Ligelizumab
Phase 3 Ig epsilon chain C region inhibitor
Docetaxel anhydrous
Phase 3 Tubulin inhibitor
Paclitaxel
Phase 3 Tubulin inhibitor
Dexchlorpheniramine
Phase 3 Histamine H1 receptor antagonist
Ciclesonide
Phase 3 Glucocorticoid receptor agonist
Triclosan
Phase 3 Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor
Amoxicillin
Phase 3 Bacterial penicillin-binding protein inhibitor
Omalizumab
Phase 2 Ig epsilon chain C region inhibitor
Denosumab
Phase 2 Tumor necrosis factor ligand superfamily member 11 inhibitor
Albuterol
Phase 2 Beta-2 adrenergic receptor agonist
Budesonide
Phase 2 Glucocorticoid receptor agonist
Zafirlukast
Phase 2 Cysteinyl leukotriene receptor 1 antagonist
Cholecalciferol
Phase 2 Vitamin D receptor agonist
Prednisone
Phase 2 Glucocorticoid receptor agonist
Formoterol
Phase 2 Beta-2 adrenergic receptor agonist
Dupilumab
Phase 2 Interleukin-4 receptor subunit alpha antagonist
Tozinameran
Phase 2 Spike glycoprotein vaccine antigen
Doxylamine
Phase 2 Histamine H1 receptor antagonist

Showing the 30 furthest along of 58 in trials.

How Its Trials Ended

2,004 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 336 whose ending is known, 54% met their primary endpoint, 4% missed it and 42% stopped early.

  • Completed, result not reported1,02051%
  • Ongoing39220%
  • Status unknown25613%
  • Met its primary endpoint1829%
  • Stopped: other or unclear744%
  • Stopped: enrollment or feasibility362%
  • Stopped: sponsor or business decision151%
  • Missed its primary endpoint141%
  • Stopped: lack of efficacy80%
  • Stopped: funding60%
  • Stopped: safety10%

FDA Orphan Designations

Approved first, then open designations, newest first
Jul 29, 2011Coccidioidin SD Skin Test AntigenFor the detection of delayed type hypersensitivity to C. immitis in individuals, 18-64 years of age, with a history of pulmonary…Allermed Labortories, Inc.Approved
Jul 31, 2003ZavescaTreatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due…IC-MedTech CorporationApproved
Mar 19, 1999Lidoderm PatchFor relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia.Teikoku Pharma USA, Inc.Approved

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Dec 17, 2020PalforziaDefatted powder of Arachis hypogaea L., semen (peanuts)StallergenesEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.